Featured Research

from universities, journals, and other organizations

Possible Treatment Found For 'Chemobrain'

Date:
June 8, 2005
Source:
University of Cincinnati
Summary:
Researchers have identified a medication effective for treating the side effects that result from chemotherapy and radiation treatments in breast and ovarian cancer patients.

Patients who take medication for cancer often find themselves with a new problem when their treatment ends.

It's called "chemobrain," a common consequence of chemotherapy that causes memory problems, confusion and difficulty in concentrating.

Symptoms of chemobrain can also include lack of focus, inability to organize daily activities, mental confusion, memory loss and decreased mental clarity.

It's estimated that chemobrain occurs in as many as 99 percent of breast and ovarian cancer patients receiving chemotherapy or radiation treatments. Sixty-one percent of these patients continue to experience fatigue and memory problems long after their cancer treatment has stopped.

Now, researchers led by the University of Cincinnati's (UC) Elyse Lower, MD, report a possible new treatment for the problem using the drug dexmethyphenidate (d-MPH).

Dr. Lower, professor of hematology/oncology at UC College of Medicine, recently described the encouraging results of a 14-month, multi-center, Phase 2 study of d-MPH to the annual meeting of the American Society of Clinical Oncology.

The 154 cancer survivors at 21 medical centers showed significant reduction in fatigue and improvement in memory when treated with dosages of 10 mg to 50 mg of d-MPH per day, Dr. Lower said, when compared with a control group receiving a placebo.

All the patients, who had a median age of 53 years, had completed at least four cycles of chemotherapy at least two months before the study began. Ninety percent of them were female (76 percent with breast cancer and 14 percent with ovarian cancer), 79 percent were white and 9 percent were African-American.

"The study showed that up to 50 mg a day of d-MPH is safe and effective for relieving chemobrain in adult cancer patients," said Dr. Lower, "and it should be considered as a treatment."

One of the study participants, Marilyn Metz, had undergone radiation and chemotherapy in 2001 to treat breast cancer.

"I couldn't concentrate or focus long enough to finish most tasks," she said. "I would start projects, but couldn't concentrate, and often left them unfinished."

It got so bad that Metz found it difficult to talk to strangers on the phone.

"I wouldn't be able to think of a key word in a sentence," she said. "I felt like the word was in back of my brain. I just couldn't drag it forward quickly enough."

Before receiving treatment for breast cancer, Metz said, she had read about possible side effects such as losing hair, but did not read anything about chemobrain.

After talking to Dr. Lower, she decided to participate in the study.

"What's the good of being successfully treated for breast cancer if your brain isn't working right?" she asked.

"I appreciate the chemotherapy and radiation killing the cancer cells, and would take it again to continue living," Metz added. "I am even more thankful that new treatments are being found to treat the fatigue and other side effects of chemobrain."

After treatment with d-MPH, she added, "I can think more clearly and have more energy--but I'm still able to take naps in the afternoon, if I feel the need."

"This medication has really helped me," Metz said. "I feel like my brain capacity is back to normal."

All participants in this trial were offered the real medication free after the double-blinded trial had ended. Metz participated in the control group and began using d-MPH following the study.

###

Coauthors of this presentation were from the UC Medical Center and Beth Israel Cancer Center, New York, N.Y.

The research was funded by Celgene Corporation based in Warren, N.J. Celgene provided medication free of charge to the study participants. Dr. Lower has no financial interests or holdings in Celgene Corporation.


Story Source:

The above story is based on materials provided by University of Cincinnati. Note: Materials may be edited for content and length.


Cite This Page:

University of Cincinnati. "Possible Treatment Found For 'Chemobrain'." ScienceDaily. ScienceDaily, 8 June 2005. <www.sciencedaily.com/releases/2005/06/050608052704.htm>.
University of Cincinnati. (2005, June 8). Possible Treatment Found For 'Chemobrain'. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2005/06/050608052704.htm
University of Cincinnati. "Possible Treatment Found For 'Chemobrain'." ScienceDaily. www.sciencedaily.com/releases/2005/06/050608052704.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins